



A**B**

Figure S1. Number of donor-reactive (A) IFN- γ and (B) IL-21 producing cells, grouped by type of rejection at the time of biopsy sampling. AMR, antibody-mediated rejection; IFN- γ , interferon gamma; IL-21, interleukin-21; PBMC, peripheral blood mononuclear cell; TCMR, T cell-mediated rejection.

Table S1. Pathology classification of 97 for-cause biopsies performed in a cohort of 103 patients.

Biopsy result and classification	Biopsies, n (N=97)
TCMR	
Suspicious forTCMR	2
1B	1
2A	17
2B	4
ABMR	
Suspicious for AMR*	6
AMR	8
ATN	51
TMA	2
Other	6

*Histologic evidence of AMR without C4d positivity and/or donor-specific antibodies.

ABMR, antibody-mediated rejection; ATN, acute tubular necrosis; TMA, thrombotic microangiopathy; TCMR, T cell-mediated rejection.

Table S2. Number of donor-reactive cells in pretransplant samples and samples taken at the time of biopsy sampling.

Samples	# IFN- γ producing cells/ 1×10^5 PBMC, median (IQR)	# IL-21 producing cells/ 3×10^5 PBMC, median (IQR)
Pretransplant sample		
No REJ vs BPAR	31 (14-48) vs 57 (35-82)	35 (12-59) vs 58 (28-114)
Presumed REJ vs BPAR	46 (33-83) vs 57 (35-82)	48 (27-109) vs 58 (28-114)
Biopsy sample		
No REJ vs BPAR	14 (5-23) vs 55 (28-87)	18 (5-54) vs 56 (42-118)
Presumed REJ vs BPAR	37 (18-56) vs 55 (28-87)	27 (21-47) vs 56 (42-118)

BPAR, biopsy-proven acute rejection; IFN, interferon; IQR, interquartile range; PBMC, peripheral blood mononuclear cell; REJ, rejection.

Table S3. Univariate analysis of variables associated with the development of BPAR within 6 months after transplantation.

Recipient and donor characteristics

	Exp (B)	95% CI	P
Recipient age, years	1.04	0.98-1.12	0.21
Total number of Tx	1.34	0.17-10.66	0.78
Deceased donor	2.09	0.54-8.04	0.28
Total HLA mismatch	1.20	0.77-1.86	0.43
PRA current	1.00	0.94-1.04	0.58
PRA historical	1.05	1.01-1.10	0.03
Positive pre-Tx IFN-G	40.89	2.83-591.50	0.006

CI, confidence interval; PRA, panel-reactive antibody; Tx, transplantation.

Table S4. IFN- γ ELISPOT assay results pretransplantation and at the time of biopsy sampling.

ELISPOT assay at time of biopsy sampling				
		Negative	Positive	TOTAL
Pretransplant ELISPOT assay	Negative	10	2	12
	Positive	13	26	39
	TOTAL	23	28	51

ELISPOT, Enzyme-Linked Immune Absorbent Spot.